IHI:NYE-iShares U.S. Medical Devices ETF (USD)

ETF | Health |

Last Closing

USD 55.97

Change

-0.96 (-1.69)%

Market Cap

N/A

Volume

0.78M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.92 (-2.16%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.32 (-2.08%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.59 (-2.69%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-1.08 (-1.43%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.04 (+0.21%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-3.90 (-4.14%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.37 (+1.40%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.37 (-1.47%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.39 (-0.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.53 (+3.19%)

USD 0.01B

ETFs Containing IHI

MSSS Northern Lights Fund Trus.. 9.63 % 0.00 %

-0.66 (-2.59%)

USD 0.10B
ETAC:CA 0.00 % 1.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.08% 76% C+ 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.08% 76% C+ 57% F
Trailing 12 Months  
Capital Gain 2.32% 86% B+ 65% D
Dividend Return 0.44% 38% F 6% D-
Total Return 2.76% 86% B+ 51% F
Trailing 5 Years  
Capital Gain 31.95% 90% A- 50% F
Dividend Return 2.57% 47% F 5% F
Total Return 34.52% 67% D+ 39% F
Average Annual (5 Year Horizon)  
Capital Gain 1.49% 43% F 42% F
Dividend Return 1.91% 43% F 33% F
Total Return 0.42% 47% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 21.84% 33% F 47% F
Risk Adjusted Return 8.73% 38% F 28% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.